Left-ventricular hypertrophy (LVH) is a cardinal manifestation of hypertensive organ damage associated with an increased cardiovascular (CV) risk. We reviewed recent literature on the prevalence of LVH, as assessed by echocardiography, in order to offer an updated information on the magnitude of subclinical alterations in LV structure in contemporary human hypertension. A MEDLINE search using key words 'left ventricular hypertrophy', 'hypertension', 'echocardiography' and 'cardiac organ damage' was performed in order to identify relevant papers. Full articles published in English language in the last decade, (1 January 2000 --1 December 2010), reporting studies in adult or elderly individuals, were considered. A total of 30 studies, including 37 700 untreated and treated patients (80.3% Caucasian, 52.4% men, 9.6% diabetics, 2.6% with CV disease) were considered. LVH was defined by 23 criteria; its prevalence ranged from 36% (conservative criteria) to 41% (less conservative criteria) in the pooled population. LVH prevalence was not different between women and men (range 37.9 --46.2 versus 36.0 --43.5%, respectively). Eccentric LVH was more frequent than concentric hypertrophy respectively, Po0.05); concentric phenotype was found in a consistent fraction (20%) of both genders. Despite the improved management of hypertension in the last two decades, LVH remains a highly frequent biomarker of cardiac damage in the hypertensive population. Our analysis calls for a more aggressive treatment of hypertension and related CV risk factors leading to LVH.
INTRODUCTION
Left ventricular hypertrophy (LVH) secondary to arterial hypertension is a complex cardiac phenotype resulting from the response of myocyte and non-myocyte components to mechanical and neuro-humoral stimuli. 1 Although the mechanisms underlying this process remain incompletely understood, available evidence from the last two decades indicates that chronic haemodynamic overload has a driving role in activating LV myocardial growth; in turn, non-haemodynamic variables (that is, genetic, ethnic, environmental and hormonal factors) modulate the extent (and type) of the hypertrophic response. 2 --4 LVH in hypertensive patients may be regarded as a powerful, independent biomarker reflecting the impact of pressure overload as well as of several risk factors 5 on the heart. Routinely assessed LVH by electrocardiography or more accurately by echocardiography, is a strong determinant of cardiovascular (CV) prognosis over and beyond conventional risk factors in both population-based studies and in selected hypertensive cohorts. 6 --8 Initial levels of LV mass and mass reduction during antihypertensive treatment define CV risk related to subclinical cardiac damage 9 and influence therapeutic strategies. 10 In recent years, observational and interventional studies addressing hypertensive LVH performed worldwide 5 --9,11,12 offered us the opportunity to update available information on the prevalence of this cardiac phenotype in human hypertension in order to evaluate the efficacy of antihypertensive therapy and the impact of preventive strategies aimed to reduce CV risk. In the present paper, we report the findings of a systematic analysis of studies focusing on echocardiographic LVH in order to determine the prevalence of this high-risk condition in a population sample of 37 700 hypertensive patients.
PATIENTS AND METHODS

Search strategy and study selection
We reviewed medical literature in order to identify articles evaluating echocardiographic LVH prevalence in hypertensive patients. A computerized search was performed using PubMed, OVID and EMBASE databases from 1 January 2000 up to 31 December 2010. The terms used to identify the studies were 'left ventricular hypertrophy', 'hypertension', 'echocardiography' and 'cardiac organ damage'. Checks of the reference lists of selected papers and pertinent reviews complemented the electronic search. Data have been extracted by two independent investigators (CC and CS); additional data have been obtained by personal contact with the authors of selected papers.
Inclusion criteria were: (1) full articles published in English in peerreviewed journals during the last decade, namely from 1 January 2000 to 1 December 2010; (2) available data on echocardiographic LVH prevalence; (3) inclusion in each study of at least 400 adult or elderly patients with hypertension defined according to current guidelines.
Only the updated or largest report was considered when multiple publications by the same research group were found. The first literature search identified 1901 papers published after 1999; of these, 81 were eligible for the analysis and only 30 could be included in the final review. 13 --42 Of the 81 studies, 23 were excluded as double or serial publications, 10 because no data on LVH prevalence in the hypertensive fraction were reported, 9 because LV mass was reported only as continuous variable and no categorical data of LVH were provided, 6 because it included less than 400 individuals and 3 because only magnetic resonance imaging was provided. A flow-chart summarizing the selection process of publications is reported in Figure 1 .
Definition of LVH and LV geometry
In all studies, LVH was defined by LV mass echocardiographically assessed and indexed to body size:body surface area (BSA) or less frequently to height or height to the allometric power of 2.7. Cut-off criteria for LVH definition were either: (a) associated with increased risk of CV events, 13 15,17 --21,29,36,38,40 convention. LV mass was calculated in all studies using necropsy-validated equations. 43, 44 Finally, increased relative wall thickness characterizing LV concentric geometry was defined according to partition values ranging from 0.43 (refs 15,27,36,38,40) to 0.50. 
Statistical analysis
The main objective of the review was to determine the rate of echocardiographic LVH in the hypertensive setting according to the criteria provided by various studies. Secondary aims were to investigate: (a) gender-related differences in prevalence rates of LVH; (b) distribution of the geometric patterns of LVH. In order to calculate the average prevalence of LVH in the pooled population, the sum of the number of patients fulfilling LVH criteria provided by the authors in each study was divided by the total number of patients (n ¼ 37 770). Data are expressed as absolute numbers, percentage, mean ± s.d. or median and inter-quartile range. Differences between groups/studies were assessed by analysis of variance. The limit of statistical significance was set at Po0.05 by two-tailed tests. 13, 30, 34 and the remaining 2 were performed in specialist out-patient centers. 19, 42 In approximately half of the studies, the effective observation period, including the echocardiographic examination, was before the year 2000.
RESULTS
Characteristics of the studies
Characteristics of the patients A common feature of analysed reports (26 out of 30) was the population study, mostly represented by selected hypertensive subjects with preserved LV systolic function, without prevalent CV diseases (that is, coronary heart disease, stroke, congestive heart failure, significant aortic and/or mitral valve disease, cardiomyopathy). 14 --33,36 --40,42 Mean age range was 44 --67 years, 52.4% were men (n ¼ 19 754). Average systolic BP ranged from 134±22 (ref. 27) to 180±29 mm Hg, 35 and diastolic BP from 75 ± 12 mm Hg 27 to 100 ± 9 mm Hg. 21, 24 As many as 993 patients (2.6%) had previous CV events. 13, 34, 35, 41 The overall prevalence of type-2 diabetes (26 studies, 34 328 patients) and obesity (11 studies, 22 473 patients) was 9.6% and 27.1%, respectively ( Figure 2 ).
From the data provided by 27 out of 30 studies, one-fifth of patients had never been treated (n ¼ 8397, 24.6%); 1843 patients (4.9%) were not receiving any antihypertensive treatment at the time of echocardiographic examination as prior anti-hypertensive drugs had been discontinued during a brief placebo wash-out period (1 --4 weeks). 13, 20, 23, 31 Among the remaining 27 460 patients, the fraction of those on antihypertensive medication ranged from 42 to 100%. Table 2 , LVH prevalence was defined according to 23 criteria, all but two based on LV mass indexed to BSA (n ¼ 12), height 2.7 (n ¼ 5) or height (n ¼ 2), BSA 1.5 (n ¼ 1) and height 2.13 (n ¼ 1). In about one-third of trials (n ¼ 12), more than one LVH definition was provided (range 2 --7). 13,16,17,21,22,29,31,36,38 --40,42 In these studies, criteria providing the highest figures of LVH were considered less conservative; conversely, criteria providing the lowest figures of LVH were considered more conservative. Gender-specific partition values and indexation of LV mass to BSA were used in the majority of trials, the BSA/height and gender/ non-gender ratio being 1.6 and 1.9, respectively. LV mass indexes equal or exceeding 125 g m À2 in men and 110 g m À2 in women (n ¼ 9) and 125 g m À2 in both sexes (n ¼ 9) were the prevalent LVH diagnostic criteria, followed, in ranking order, by 51 
LVH criteria As shown in
Type of LVH
As for LV geometric patterns, the eccentric pattern was more prevalent than the concentric one in 14 out of 18 studies (n ¼ 20 656 patients) providing this kind of information. On the whole, 5608 (27.1%) and 4905 patients (23.7%) were found to fulfill the more and less conservative criteria for eccentric LVH, respectively; the corresponding numbers for concentric LVH were 3575 (17.3%) and 3998 (19.3%), respectively. These differences were significant regardless the criteria used (P ¼ 0.04 for more restrictive criteria, P ¼ 0.03 for less restrictive ones). Finally, information on gender-related LVH patterns were limited to a few studies (n ¼ 5 including 4384 patients, 2259 men). 13, 14, 17, 21, 36 Eccentric LVH prevalence tended to be higher in women than in men (42 --61 versus 32 --45%, respectively, P ¼ 0.13); concentric hypertrophy had a similar range in both genders (24 --33 versus 25 --32%).
DISCUSSION
The present analysis of 30 studies published in the last decade provides one of the largest database on echocardiographic LVH prevalence in a hypertensive population of 37 700 patients from different hypertensive cohorts and from the hypertensive fraction of the general population. The main findings of our work are the following: (1) alterations in cardiac structure are frequently found both in treated and untreated hypertensives, although within a wide range of values in the different reports (9 --77%); LVH, indeed, is present in approximately 36% of the pooled population according to more restrictive diagnostic criteria and in 41% according to less conservative ones; (2) gender-specific analyses indicate that LVH prevalence is similar in women (37.9 --46.2%) as in men (36.0 --43.5%); (3) eccentric LVH, regardless the criteria used, is significantly more prevalent than concentric hypertrophy; this latter phenotype that is associated with an adverse prognosis, is present in a consistent fraction of both genders (approximately 20%).
Overall, our results update and expand previous evidence by showing that echocardiographic LVH has a wide prevalence among different hypertensive settings as a likely result of demographic and clinical factors, such as age, gender, severity and time of exposure to BP overload, coexistent diseases and risk factors. The analysis of the impact of the different factors on LVH is beyond the aim of this review. The highest figures of echocardiographic LVH prevalence (475%) are reported in studies examining patients with resistant hypertension 35 and electrocardiographic evidence of LVH;
13 these studies include a significant fraction of patients with prior CV complications and the highest BP levels. Conversely, the lowest (o30%), although clinically relevant, rates of LVH are found in hypertensives surveyed in population-based studies 14, 18, 27 or in middle-aged, recently diagnosed, untreated hypertensives. 25, 28, 31, 32, 38 From these data, two considerations can be made: (1) a consistent fraction of treated hypertensive patients are still exposed to a high CV risk as antihypertensive treatment is unable to normalize BP and consequently reverse alterations in cardiac structure; (2) a noticeable portion of hypertensive patients (30%) enrolled in the examined studies were untreated, despite having a cardinal manifestation of organ damage such as LVH; this suggests that unsolved issues in primary prevention of CV disease include not only unsatisfactory BP control but also poor awareness of the hypertensive status and delay in hypertensive treatment.
It is worth noting that LVH in the analysed studies was defined according to as many as 23 criteria based on different echocardiographic methods (that is, M-mode or 2-dimensional recordings, ASE or PENN convention) and formulae. The heterogeneity in defining LVH phenotype is related to several factors including a poor consensus about the best method for normalizing LV mass to body size and its application in different clinical settings. 45, 46 Furthermore, new diagnostic criteria derived from reference values in healthy population samples have been proposed by various research groups in addition to well established and prognostically validated cut-offs. The limitations of comparing findings based on different diagnostic criteria (gender or non-gender specific, indexed to BSA or height, more or less restrictive), as in the present survey, call for adoption of definition(s) of echocardiographic LVH based on reference thresholds with proven prognostic value and recommended by scientific societies.
A further aspect of our study is that in a gender-based analysis of 16 033 patients representing 42% of the pooled population (51% men), LVH prevalence was not significantly different between genders. This finding, however, should be taken with caution due to the heterogeneity of diagnostic criteria (gender and non-gender specific) used to define LVH in the various studies. A greater prevalence of LVH in women was reported by Levy et al. 47 in the Framingham population. Furthermore, a higher likelihood of LVH in treated hypertensive women has been recently observed by Okin et al. 48 who reported that regression of electrocardiographic LVH in response to antihypertensive treatment was less pronounced in women after adjustment for major factors impacting on LVH regression. It is worth noting, however that other studies failed to observe any gender difference or showed the opposite trend. 49, 50 One interesting result of the present study is that eccentric hypertrophy resulted the most frequent abnormal LV pattern, the eccentric/concentric ratio ranging from 1.37 to 1.40; it should be observed, however, that concentric LVH, a geometric pattern associated with worse CV prognosis, 20, 51, 52 was present in a consistent fraction of patients (approximately one-fifth). The high prevalence of concentric LVH raises major concerns about contemporary management of hypertension and claims for more appropriate interventions in BP and related risk control. The question whether the prevalence of hypertensive LVH in the present analysis is representative of clinical practice may be raised, as patients mostly free from overt CV disease (97.4%) and type-2 diabetes (90.4%) were included. As these two conditions strongly associated with LVH, are definitely more frequent in hypertensive patients cared by general practitioners or specialists in the real world, 53 it should be concluded that LVH prevalence in current practice is probably higher than in the present analysis.
A recent retrospective analysis in a large population (n ¼ 35 602, mean 60 yrs) referred for routine echocardiography, 52 reported that LVH was present only in 11% of subjects; alterations in cardiac structure and geometry were strictly associated with older age and greater prevalence of obesity. Unfortunately, no information on hypertension prevalence and treatment neither data on LVH prevalence in the hypertensive fraction of this report were provided. In addition, a partition value indexed to BSA (that is, 116/104 g m À2 ) instead of height to allometric power of 2.7 may have substantially underestimated LVH prevalence in a population with an elevated prevalence of obese subjects.
Some other aspects of the present analysis deserve to be briefly discussed. First, our findings are not fully applicable to nonCaucasian ethnicities, as our series comprised approximately 80% of Caucasian individuals. Second, although all selected studies were published in the last decade, about one half of the reports included echocardiographic investigations carried out in the nineties or even before. Nonetheless, prevalence rates of LVH in recent studies tended to be even higher (39 versus 35%) than in those previously performed (data not shown). This temporal trend suggests that hypertensive LVH, as a marker of organ damage, is not slowing down.
In conclusion, our analysis of a large representative sample of hypertensive patients from studies completed worldwide over the past decade, clearly documents that LVH remains a frequent adverse phenotype in contemporary human hypertension, in both genders, despite the improvements in diagnostic and therapeutic approaches. This impressive evidence supports a role of echocardiography in the assessment of target organ damage in clinical practice and claims for more effective comprehensive prevention strategies in the hypertensive population.
